Semaglutide 14mg tablets: the misconception worth clearing up first

The 14mg tablet exists, it just isn't a weight-loss medicine

Rybelsus comes in three strengths: 3mg, 7mg and 14mg. It is semaglutide, the same active ingredient in Wegovy, but the licence covers glycaemic control in adults with type 2 diabetes, not body-weight reduction. The 14mg dose is the maintenance level in the Rybelsus schedule, reached after time at 3mg and 7mg. Prescribers make that decision based on a patient's diabetes management, not their weight.

People searching for semaglutide 3mg tablets or the 7mg or 14mg variants are often not aware of this split. The confusion is understandable: same molecule, same manufacturer (Novo Nordisk), similar-looking packs. But the licences are legally distinct, and a pharmacist cannot substitute one product for the other. If you are looking for an oral semaglutide option for weight management, you are looking at a different product entirely.

Our overview of oral semaglutide tablets for weight loss sets out the full picture of how the approved product works and what to expect from it.

The dosing schedule for oral semaglutide approved for weight loss (and why 25mg is the number to know

When the MHRA approved Wegovy tablets on 11 June 2026) making the UK the first country in Europe to licence an oral GLP-1 medicine for weight management, the approved dose ladder was: 1.5mg, then 4mg, then 9mg, and finally 25mg as the maintenance dose. There is a minimum of one month at each level. That 25mg maintenance dose is roughly 1.8 times the 14mg Rybelsus ceiling, and the formulation itself is different: Wegovy tablets use an absorption enhancer called SNAC to get semaglutide across the gut wall reliably in an oral form designed for weight management rather than diabetes care.

Trial data from the OASIS 4 phase-3 study (307 adults with obesity or overweight plus at least one weight-related condition) showed an average weight reduction of around 13.6% versus roughly 2.4% on placebo over 64 weeks. Among participants who adhered fully to treatment, the figure was approximately 16.6%. That fuller-adherence result only applies to that group and must be read in its proper context; the average for all participants is the more representative number. You can read about what the evidence says on weight loss from semaglutide tablets in more detail.

The MHRA's approval announcement and the medicine's Summary of Product Characteristics (both publicly available) are the authoritative sources on the licensed indication and dose schedule. Any other tablet strengths described online in relation to weight loss are not part of the approved UK product.

How to take oral semaglutide for weight loss (and one quick check before you start

Wegovy tablets are taken once daily, first thing in the morning, on a completely empty stomach with a small amount of plain water) around 120ml maximum. Crucially, you then wait at least 30 minutes before eating, drinking anything other than plain water, or taking any other oral medicine. That window matters because the absorption mechanism depends on a fasted, low-volume gut environment. Missing the gap, or having coffee before the tablet, meaningfully reduces how much semaglutide reaches your bloodstream.

One practical checking habit worth building from day one: keep the pack on the kitchen counter rather than the medicine cabinet. Before the kettle goes on, the tablet goes in. That sequence makes the 30-minute wait almost automatic rather than something to remember mid-breakfast.

Storage is simpler than the injection form, no refrigeration. Wegovy tablets are kept at room temperature, which makes them considerably more straightforward when travelling. The Wegovy tablet overview covers storage, the absorption window and what to expect in the first weeks.

Side effects follow a similar GI-led pattern to the injectable form: nausea, loose stools, indigestion and reduced appetite are the most commonly reported, particularly when a new dose level starts. In the OASIS 4 trial, around 74% of participants on active treatment reported at least one gastrointestinal side effect (versus 42% on placebo); most were mild to moderate and settled as the body adjusted. The full semaglutide tablets guide includes more detail on managing the adjustment period.

Who can access this medicine and through what route

The licensed eligibility for Wegovy tablets mirrors the injection form: adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. A BMI figure alone does not determine access; the prescriber reviews the complete clinical picture, including any contraindications or medicines that might interact.

As of summer 2026, Wegovy tablets are not available on the NHS, a NICE appraisal has not yet taken place. That means access is currently through a private prescription following a clinical consultation. A useful overview of the options available in the UK sits on the Wegovy tablet UK access page. For anyone considering the injectable form alongside the tablet option, our weight-loss treatment overview sets out both pathways side by side, which can help frame the conversation with a prescriber.

Prescriptions for semaglutide tablets, whether for diabetes or weight management, require a formal clinical assessment. If you want to explore whether Wegovy tablets might be clinically suitable for you, the next step is a consultation with a qualified prescriber rather than a product search. Our clinical team reviews every consultation personally.